Jubilant Pharmova gets 8 USFDA obervations for Nanjangud facility
Noida: Jubilant Pharmova Limited has recently announced that the United States Food and Drug Administration (USFDA) has issued eight observations pursuant to the completion of the inspection at the company's API manufacturing facility at Nanjangud, India.The inspection was concluded on December 13, 2022. "The company will submit an action plan on the observations and will engage with US FDA...
Noida: Jubilant Pharmova Limited has recently announced that the United States Food and Drug Administration (USFDA) has issued eight observations pursuant to the completion of the inspection at the company's API manufacturing facility at Nanjangud, India.
The inspection was concluded on December 13, 2022.
"The company will submit an action plan on the observations and will engage with US FDA for next steps," the company stated in a BSE filing.
Read also: Jubilant Generics Roorkee facility determined as official action indicated
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd